Stock Research: Ocular Therapeutix

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Ocular Therapeutix

NMQ:OCUL US67576A1007
13
  • Value
    14
  • Growth
    6
  • Safety
    Safety
    53
  • Combined
    4
  • Sentiment
    73
  • 360° View
    360° View
    13
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Ocular Therapeutix, Inc. is a fully-integrated biopharmaceutical company focused on eye care. The company leverages its ELUTYX bioresorbable hydrogel-based formulation technology for its commercial product DEXTENZA (for ocular inflammation and pain, and allergic conjunctivitis) and investigational product candidates AXPAXLI (for retinal disease) and PAXTRAVA (for open-angle glaucoma or ocular hypertension). The ELUTYX technology provides delivery solutions for therapies for various eye diseases including wet age-related macular degeneration (wet AMD), NPDR, DME, proliferative diabetic retinopathy, retinal vein occlusion, and other conditions. In the last fiscal year, the company had a market cap of $1787 million, profits of $58 million, revenue of $64 million, and 274 employees.

more

ANALYSIS: With an Obermatt 360° View of 13 (better than 13% compared with alternatives), overall professional sentiment and financial characteristics for the stock Ocular Therapeutix are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Ocular Therapeutix. The consolidated Sentiment Rank has a good rank of 73, which means that professional investors are more optimistic about the stock than for 73% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 53 or better than 53% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 14, meaning that the share price of Ocular Therapeutix is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 6. ...read more

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 23-Apr-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
14 23 16 35
Growth
6 21 95 93
Safety
Safety
53 57 10 45
Sentiment
73 50 63 73
360° View
360° View
13 24 25 83
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
52 100 76 53
Opinions Change
15 50 50 91
Pro Holdings
n/a 18 60 49
Market Pulse
77 34 24 28
Sentiment
73 50 63 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
14 23 16 35
Growth
6 21 95 93
Safety Safety
53 57 10 45
Combined
4 11 25 70
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
13 12 34 46
Price vs. Earnings (P/E)
70 30 30 30
Price vs. Book (P/B)
23 42 5 20
Dividend Yield
1 1 1 1
Value
14 23 16 35
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
49 61 76 89
Profit Growth
8 6 39 88
Capital Growth
28 26 85 83
Stock Returns
36 47 87 15
Growth
6 21 95 93
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
55 34 17 41
Refinancing
72 65 51 71
Liquidity
22 32 30 24
Safety Safety
53 57 10 45

Similar Stocks

Discover high‑ranked alternatives to Ocular Therapeutix and broaden your portfolio horizons.

Walt Disney

NYQ:DIS
Country: USA
Industry: Movies & Entertainment
Size: XX-Large
Full Stock Analysis

ResMed

NYQ:RMD
Country: USA
Industry: Health Care Equipment
Size: X-Large
Full Stock Analysis

Corteva

NYQ:CTVA
Country: USA
Industry: Fertilizers & Agricultural Chemicals
Size: X-Large
Full Stock Analysis

Microsoft

NSQ:MSFT
Country: USA
Industry: Systems Software
Size: XX-Large
Full Stock Analysis

Frequently Asked
Questions

The value case is weak (expensive and low Growth Rank), but sentiment is strong and financing is safe. This scenario may indicate future growth not yet in current financials. This is a speculative choice for investors with a high-risk appetite who are betting on the positive sentiment and safe financing to sustain a long-term turnaround.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: